Comparative study of seven commercial yeast identification systems

P E Verweij, I M Breuker, A J M M Rijs, J F G M Meis

Abstract
Aims—To compare the performance of seven commercial yeast identification methods with that of a reference method, and to compare the costs of the commercial kits.
Methods—Clinical yeast isolates (n = 52), comprising 19 species, were identified using Vitek, Api ID 32C, Api 20C AUX, Yeast Star, Auxacolor, RapID Yeast Plus system, and Api Candida and compared with a reference method which employed conventional tests.
Results—The percentage of correctly identified isolates varied between 59.6% and 80.8%. Overall, the highest performance was obtained with Api Candida (78.8%) and Auxacolor (80.8%). Among germ tube negative yeast isolates, Auxacolor and Api Candida both identified 93.1% of isolates correctly. All systems failed to identify C norvegensis, C catenulata, C haemulonii, and C dubliniensis. In comparison with Auxacolor, the Api Candida is less expensive and requires less bench time.
Conclusions—Auxacolor and Api Candida appeared to be the most useful systems for identification of germ tube negative yeast isolates in clinical microbiology laboratories, although one should be aware that several germ tube negative Candida species cannot be identified by these systems.

Keywords: yeasts; commercial kits

Over the past decade the significance of infections by yeasts has increased, especially those caused by germ tube negative yeasts.1 Given the variable susceptibility of different species of yeasts to antifungal agents, the rapid and correct identification is of clinical importance. Furthermore, the identification of yeast isolates to species level makes it possible to study the epidemiology of colonisation and infection and the transmission of infections in hospitals. Conventional identification methods, however, are laborious and time consuming. Therefore, rapid commercially available identification methods have been developed which allow for identification of germ tube negative yeasts within 48 hours. In this study, we have evaluated the performance of seven commercial identification methods with clinical yeast isolates. The performance was determined by comparing the identification by each commercial kit with that by a reference method. The costs of the kits for routine identification were also compared.

Methods
Isolates
Fifty two clinical yeast and yeast-like fungal isolates were used in this study, including 19 species: Candida albicans (n = 7 isolates), C krusei (9), C glabrata (4), C guilliermondii (2), C catenulata (2), C haemulonii (1), C inconspicua (2), C kefyr (4), C lusitaniae (2), C magnoliae (1), C dubliniensis (1), C norvegensis (2), C parapsilosis (3), C tropicalis (3), Cryptococcus neoformans (4), Geotrichum candidum (1), C capitatum (1), Rhodotorula rubra (1), and Saccharomyces cerevisiae (2). All isolates were cultured from patients admitted to the University Hospital Nijmegen. The selection of isolates was based on the distribution of genera and species recovered in routine clinical practice in our hospital rather than on the presence of the fungus in the database of the commercial kits. The isolates had been stored at -70°C until use. After thawing, each isolate was subcultured onto Sabouraud chloramphenicol medium for control of purity of the isolates. One colony was subcultured on Sabouraud chloramphenicol agar plates and incubated at 30°C.

Identification systems
Isolates were identified by a reference method using conventional tests for assimilation of carbohydrates including D-galactose, D-xylene, maltose, cellobiose, lactose, raffinose, rhamnose, L-arabinitol, myo-inositol, 2-keto-D-gluconate, L-lactate, citrate, L and D-arabinose, D-gluconate, L-sorbosucrose, D-ribose, ribitol, xylitol, D-mannitol, nitrate, nitrit, ethylamine, and creatinine. Fermentation of glucose, resistance to cycloheximide, growth at 37°C and 42°C, and macroscopic and microscopic morphology2,3 were also determined.

Seven commercial yeast identification kits were evaluated: Vitek (bioMérieux Vitek, Hazelwood, Missouri, USA), Api ID 32C (bioMérieux, Lyon, France), Api 20C AUX (bioMérieux, France), Yeast Star (CLARC Laboratories, Heerlen, The Netherlands), Auxacolor (Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France), RapID Yeast Plus system (Innovative Diagnostic Systems, Norcross, Georgia, USA), and Api Candida (bioMérieux, France). Each system was used according to the manufacturer’s instructions.

The Vitek card comprises of 30 wells which contain 26 biochemical broths and four negative control broths. The cards are incubated at 30°C
The performance of each of the commercial identification systems is shown in Table 1. The performance was analysed for all yeasts and for the eight most frequently cultured germ tube negative yeasts at our hospital, which include Candida glabrata, C. krusei, C. parapsilosis, C. tropicalis, and Saccharomyces cerevisiae (29 isolates). The proportion of correctly identified yeasts varied between 59.6% and 80.8%. We had difficulties with turbidity reading with API ID 32C and API 20C AUX. In addition, colour change reading was sometimes difficult for RapID Yeast Plus. Additional tests were necessary with Vitek, API 20C AUX, RapID Yeast Plus, and Api Candida. Furthermore, several germ tube negative yeasts which are regularly recovered from clinical specimens, such as C. norvegensis, were missing in the databases of Vitek, Yeast Star, and RapID Yeast Plus System. C. norvegensis was among four yeast isolates that were not correctly identified by any of the systems. This was also the case for C. catenulata, C. haemulonii, and C. maltosa. C. haemulonii was not included in any of the manufacturers’ databases and C. catenulata only in that of API ID 32C. C. maltosa was misidentified by the reference method, to ensure that the identification was performed by experienced personnel. The reference method, Auxacolor, and RapID Yeast Star Plus were performed at the University Hospital Nijmegen, Vitek at the University Hospital Rotterdam, API ID 32 at Bronovo Hospital in The Hague, API 20C AUX at Janssen Research Foundation in Beerse, Belgium, and Yeast Star at Catharina Hospital in Veldhoven, The Netherlands. The 52 yeast isolates were blinded and sent to each participating institute.

Results

The performance of each of the commercial identification systems is shown in Table 1. The performance was analysed for all yeasts and for the eight most frequently cultured germ tube negative yeasts at our hospital, which include C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, and Saccharomyces cerevisiae (29 isolates). The proportion of correctly identified yeasts varied between 59.6% and 80.8%. We had difficulties with turbidity reading with API ID 32C and API 20C AUX. In addition, colour change reading was sometimes difficult for RapID Yeast Plus. Additional tests were necessary with Vitek, API 20C AUX, RapID Yeast Plus, and Api Candida. Furthermore, several germ tube negative yeasts which are regularly recovered from clinical specimens, such as C. norvegensis, were missing in the databases of Vitek, Yeast Star, and RapID Yeast Plus System. C. norvegensis was among four yeast isolates that were not correctly identified by any of the systems. This was also the case for C. catenulata, C. haemulonii, and C. maltosa. C. haemulonii was not included in any of the manufacturers’ databases and C. catenulata only in that of API ID 32C. C. maltosa was misidentified by the reference method.

Table 1 Performance of seven commercial identification systems with 52 clinical yeast isolates

<table>
<thead>
<tr>
<th>Identification system</th>
<th>All isolates (n=52): identification (%)</th>
<th>Germ tube negative isolates (n=29): identification (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Correct</td>
<td>Incorrect</td>
</tr>
<tr>
<td>Vitek</td>
<td>59.6</td>
<td>15.4</td>
</tr>
<tr>
<td>Api ID 32C</td>
<td>63.5</td>
<td>34.6</td>
</tr>
<tr>
<td>Api 20C AUX</td>
<td>59.6</td>
<td>36.5</td>
</tr>
<tr>
<td>Yeast Star</td>
<td>59.6</td>
<td>40.4</td>
</tr>
<tr>
<td>Auxacolor</td>
<td>80.8</td>
<td>7.7</td>
</tr>
<tr>
<td>RapID Yeast Plus</td>
<td>76.9</td>
<td>11.5</td>
</tr>
<tr>
<td>Api Candida</td>
<td>78.8</td>
<td>13.5</td>
</tr>
</tbody>
</table>

Additional tests are recommended in the case of low discrimination by all systems, and include morphological characteristics such as production of germ tubes, chlamydospores, colony morphology, presence of capsules, and ability to form mycelium, pseudomycelium, arthroconidia, or blastoconidia. For API ID 32C, seven supplementary tests can be read.

The Auxacolor includes morphological characteristics in the numerical profile.

Interpretation

A “correct identification” was defined as a numerical profile obtained with a system that was included in the manufacturer’s database and in accordance with the identification by the reference method. Isolates that required additional tests to achieve a correct identification were also grouped in this category. Isolates that produced a numerical profile that was not listed in the manufacturer’s database were classified as “non-identification.” When the identification with the commercial system was not in accordance with that obtained by the reference method the result was classified as “incorrect identification.”

Study design

The identification was performed in different institutes in The Netherlands and Belgium that used a commercial kit for routine identification, to ensure that the identification was performed by experienced personnel. The reference method, Auxacolor, and RapID Yeast Star Plus were performed at the University Hospital Nijmegen, Vitek at the University Hospital Rotterdam, API ID 32 at Bronovo Hospital in The Hague, API 20C AUX at Janssen Research Foundation in Beerse, Belgium, and Yeast Star at Catharina Hospital in Veldhoven, The Netherlands. The 52 yeast isolates were blinded and sent to each participating institute.

Costs

The costs per test were calculated for each of the commercial kits and of additional tests if necessary. The mean bench time spent for identification was also calculated.
Identification methods

<table>
<thead>
<tr>
<th>Identification system</th>
<th>Cost/test (€)</th>
<th>Bench time (min)</th>
<th>Cost/identification (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auxagram reference method</td>
<td>1.92</td>
<td>18</td>
<td>4.74</td>
</tr>
<tr>
<td>Vitek</td>
<td>2.96</td>
<td>12</td>
<td>4.84</td>
</tr>
<tr>
<td>Api ID 32C</td>
<td>2.96</td>
<td>12</td>
<td>4.84</td>
</tr>
<tr>
<td>Api 20C AUX</td>
<td>2.87</td>
<td>12</td>
<td>4.76</td>
</tr>
<tr>
<td>Yeast Star</td>
<td>1.58</td>
<td>10</td>
<td>3.15</td>
</tr>
<tr>
<td>Auxacolor</td>
<td>4.44</td>
<td>7</td>
<td>5.54</td>
</tr>
<tr>
<td>RapID Yeast Plus</td>
<td>5.54</td>
<td>10</td>
<td>7.11</td>
</tr>
<tr>
<td>Api Candida</td>
<td>3.39</td>
<td>5</td>
<td>4.17</td>
</tr>
</tbody>
</table>

Considerable variation of costs and bench time was observed for the identification systems (table 2).

Discussion

In most clinical microbiology laboratories commercial identification systems are used for identification of germ tube negative yeasts. The performance of commercial identification systems varied considerably. Overall, Auxacolor and Api Candida showed the highest percentage of correctly identified yeasts, including the germ tube negative yeasts. Auxacolor also showed the lowest percentage of incorrect identification. An advantage of the Auxacolor is that the isolates are not only identified by biochemical characteristics, but morphological appearance and ability to form mycelia are also taken into account, which reduces the need to perform additional tests. The system is, however, relatively expensive.

The identification rates of the kits evaluated in the present study were lower than those reported previously, which are greater than 80%. Identification rates, however, depend on the panel of yeasts which is used to evaluate the kit. The present study was designed to evaluate the performance of the kits in the setting of identification of isolates encountered routinely in a clinical microbiology laboratory. It is important to note that even kits that are considered reliable show lower identification rates in this setting, since yeast isolates are included which are not listed in the database of the kit. In the latter case a non-identification result is preferable to an incorrect identification.

C dubliniensis has only recently been described as a cause of oropharyngeal candidosis in HIV positive patients. C dubliniensis is difficult to distinguish from C albicans since both species produce germ tubes and chlamydospores. In clinical microbiology laboratories yeast isolates that produce germ tubes and chlamydospores are considered to be C albicans, and no additional tests are performed. However, both species can be differentiated if discriminative media, such as CHROMagar candida plates, are used for primary isolation.

Tests such as abundant production of chlamydospores and the ability to grow at 45°C may also help to differentiate between the two species. The commercial identification systems presently available fail to identify this new species correctly. However, if a commercial system identifies a germ tube positive yeast as C albicans, one should consider C dubliniensis if the strain fails to utilise xylose or to elaborate β-glucosidase.

Independent of the system used, morphological examination of yeast isolates remains essential to obtain a correct identification; in addition, both Auxacolor and Api Candida are useful and rapid systems for the routine identification of germ tube negative yeasts.

We thank the consultant microbiologists Drs H Endtz, A Jansz, and A Horrevorts, and Prof F C Odds for identifying the yeast isolates.

Comparative study of seven commercial yeast identification systems.

P E Verweij, I M Breuker, A J Rijs and J F Meis

doi: 10.1136/jcp.52.4.271

Updated information and services can be found at:
http://jcp.bmj.com/content/52/4/271

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/